APOE ε4 positive patients suffering severe traumatic head injury are more prone to undergo decompressive hemicraniectomy
2017 (English)In: Journal of clinical neuroscience, ISSN 0967-5868, E-ISSN 1532-2653, Vol. 42, p. 139-142Article in journal (Refereed) Published
Abstract [en]
OBJECT: In this paper we tested the hypothesis if patients with severe traumatic brain injury and presence of the apolipoprotein E (APOE) ε4 allele are more prone to undergo the surgical procedure decompressive hemicraniectomy (DC) in order to bring the intracranial pressure (ICP) under control.
METHODS: In this prospective consecutive study patients with sTBI were enrolled (n=48). Inclusion criteria were arrival to our level one trauma university hospital within 24h after trauma, patient age between 15 and 70years, Glasgow Coma Scale (GCS) score ≤8 at the time of intubation and sedation, an initial cerebral perfusion pressure >10mmHg. Venous blood was sampled for APOE genotype determination. Clinical outcome at 6months after injury was assessed with the Extended Glasgow Outcome Scale (GOSE). All surgical procedures needed for each patient were registered.
RESULTS: Patients with the APOE ε4 allele were significantly overrepresented in the DC group. In the APOE ε4+DC group, ICPmax and ICPmean during the first 36h were significantly higher and GOSE was significantly worse at 6months.
CONCLUSION: Our data suggest that patients with the APOE ε4 allele are predisposed for the need of DC more often than patients without the APOE ε4 allele. Thus, it seems to be of importance to consider the APOE genotype in patients suffering severe traumatic brain injury in order to forecast the need for a more exquisite intensive care.
Place, publisher, year, edition, pages
Elsevier, 2017. Vol. 42, p. 139-142
Keywords [en]
APOE ε4; Hemicraniectomy; Severe traumatic brain injury
National Category
Neurology
Research subject
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-57343DOI: 10.1016/j.jocn.2017.03.024ISI: 000405535800030PubMedID: 28372905Scopus ID: 2-s2.0-85016417394OAI: oai:DiVA.org:oru-57343DiVA, id: diva2:1098840
Note
Funding Agencies:
Department of Pharmacology and Clinical Neuroscience, Umeå University
Tore Nilsson Found
Kempe Found
Capio Research Found
2017-05-262017-05-262020-12-01Bibliographically approved